Trending...
- Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
- Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
- Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Lineus Medical Completes UK Registration for SafeBreak® Vascular
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- Anne Seidman: Within the Lines
- How Democrats Made Healthcare More Expensive in 2026
- Inkdnylon Launches Bilingual Ask Inkdnylon Platform
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
- Mitchell Sipus Releases New Dance Single "Can U"
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
- The New Monaco of the South (of Italy)
- OctoNerv Completes Functional Prototype of Electronic Breast Nipple Implant (EBNI)
- Zivra AI Launches Real-Time Business Health and Financial Intelligence for SMEs
- Obey God Clothing Launches Urban Christian Apparel Line Serving All Ages
- PA Golf Cart World Launches NEV Pre-Inspection & Compliance Service for 2026
- Dr. Curtis Rasmussen Shares Leadership and AI Insights on Lead Empowered TV